Type 2 Diabetes (T2D) - Pipeline Analysis

Publication ID:

IQ40517002

Publication Date:

July 6, 2015

Pages:

174

Publisher:

IQ4I

Countries:

Global [1]

USD 3,600.00

Pharma & Healthcare [2]

Diseases [3]

Healthcare [4]

Description:

Type 2 Diabetes (T2D) Pipeline Analysis鈥� gives comprehensive insight on the various drugs being developed for the treatment of T2D.

The global Type 2 Diabetes (T2D) market is estimated to be $31.3 billion in 2014 and is expected to grow at a CAGR of mid-range single digit from 2015 to 2021 to reach $46.7 billion by 2021.

The report covers all the drugs being developed in various phases (Discovery, Preclinical, Clinical & 麻豆原创ing). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, monoclonal antibodies, stem cell therapies, Gene therapies, Recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations. The report also covers some of the hot targets in research for T2D treatments and disease progression biomarkers.听

听

This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Type 2 Diabetes (T2D) Drug market. The report also provide strategic insights on medicines that are likely to have an impact on T2D treatment space and potentially alter standards of care in T2D in the foreseeable future.听

听

Current therapies are focused on the treatment of hyperglycemia than on pancreatic Beta cell dysfunction and they lose efficacy over time as both endogenous insulin secretion and insulin sensitivity decrease. There is a need for type 2 diabetes therapies that act in concert with available agents to provide adequate glycemic control without causing hypoglycemia and weight gain, which are associated with increase in cardiovascular risk. Hence, it provides a tremendous opportunity for upcoming therapies specific to T2D such as MAbs, stem cell-based, gene therapies and RNA-based therapies. These modalities may provide beta-cell protection, regeneration, mass increase with additional benefits of weight loss, triglyceride lowering and kidney protection.

听

Key Findings:听

听

- The global Type 2 Diabetes (T2D) market is estimated to be $31.3 billion in 2014 and is expected to grow at a CAGR of mid-range single digit from 2015 to 2021 to reach $46.7 billion by 2021.

听

- Factors contributing to the market growth include, technological advancements leading to emergence of novel therapeutics & mechanisms, increasing incidence of diabetes, obesity & cardiac diseases, alteration in lifestyle and high unmet needs in current treatments options.听

听

- IQ4I analysis indicates that 37% of candidates are in Pre-clinical stage followed by 20% in PII clinical.

听

- In addition to small molecules, there is growing interest among researchers on large molecules and novel therapies, such as:

RNA-based therapy

Stem cell therapy

Monoclonal antibody-based therapy

Gene therapy

Recombinant proteins听

听

Some of the key sections covered in the report are given below:

听

1. Epidemiology听

听

In this section, epidemiology of T2D is reviewed to understand potential significance and impact of the disease.

- Global T2D prevalence rates听

听

2. Hot Targets, Mechanisms & Therapies听

听

In this section, various T2D associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for diabetes along with disease progression biomarkers associated with T2D.听

听

3. 麻豆原创 analysis听

听

In market analysis section, global Type 2 Diabetes (T2D) drugs market is indicated region-wise along with the CAGRs forecasted from 2015-2021.

听

- Forecasting model for T2D market

- T2D market dynamics

- Global and regional T2D drugs market

- Cost-burden diabetes care in U.S听

听

4. Pipeline Analysis:听

听

Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, development & marketing section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule.听

听

- Pipeline analysis by developmental stage (Discovery to 麻豆原创ing)听

听

- Pipeline analysis by modalities:

Monoclonal Antibodies pipeline analysis

RNA-therapeutics pipeline analysis

Stem cell therapy pipeline analysis

Gene therapy pipeline analysis

Recombinant protein pipeline analysis听

听

- Pipeline analysis by leading players & Target analysis

听

- Drug analysis based on mechanism (alpha-cell secretion, alpha-cell mass decline, kidney protection, insulin sensitizers, Triglyceride lowering, weight loss, 脽-cell mass increase, 脽-cell mass decline, 脽-cell protection & 脽-cell regeneration).听

听

5. Key Players Analysis:听

听

The key player鈥檚 analysis section provides an in-depth understanding of various companies working on Type 2 Diabetes (T2D) and their Pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.听

听

- Global key players overview

- Global key players Pipeline data (Discovery, Pre-clinical, Clinical & 麻豆原创ing)

- Global key players deals (Collaborations, Licensing, Service agreements, grants, funds)

Table Of Contents:

1. Report Description听

听

2. Introduction

- Causes & Symptoms

- Diagnosis

- Unmet needs

- Epidemiology

- Current therapies

听

3. Hot Targets, Mechanisms & Therapies

- Novel Disease mechanisms & therapies

- Leading & hot targets of T2DM

- Novel targets of Diabetes

- T2D disease progression biomarkers

听

4. 麻豆原创 Data

- Forecasting model

- 麻豆原创 dynamics

- 麻豆原创 sizing

- Cost burden

听

5. Pipeline Analysis

- Development stage

- Leading players

- Therapeutic segmentation

- Innovative approaches

- Target analysis

Small molecules

- Pipeline

- Competitive landscape

Large molecules

- Pipeline

- Competitive landscape听

听

6. Monoclonal ABs

- Pipeline

- Competitive landscape听

听

7. Stemcell Therapy

- Pipeline

- Competitive landscape听

听

8. Rna Based Therapeutics

- Pipeline

- Competitive landscape听

听

9. Genetherapy

- Pipeline

- Competitive landscape

听

10. Recombinant Fusion Proteins

- Pipeline

- Competitive landscape

听

11. Drug Analysis Based On Mechanism

听

12. Major Players

- Company Profiles

- Overview, Pipeline & Deals

听

13. References

Companies Mentioned:

Addex Therapeutics
Amgen
Astrazeneca
Boehringer Ingelheim
Connexios Life Systems
Eli & Lilly
Ember Therapeutics
Glaxosmithkline
Johnson & Johnson
Merck & Co
Mesoblast Biopharma Ltd
Poxel Sa
Takeda Pharmaceuticals
Xoma Corporation

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.